Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives

Elkhenany, Hoda; Shekshek, Ahmed; Abdel-Daim, Mohamed M.; El‐Badri, Nagwa

doi:10.1007/5584_2019_441

Cited by 9 publications

(6 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Much as we attribute the success of this HCC therapeutic approach to the interaction between miR-27a-3p and GOLM1, we are also cognizant of the fact that miR-27a-3p is delivered together with other contents of mesenchymal stem cells that are known for their cell regeneration ability [27]. Various groups have researched on the use of mesenchymal stem cells to treat liver diseases such as liver fibrosis, and more recently HCC with various degrees of successes [28][29][30]. It is therefore likely that the effect seen could have been due to the cell regenerative ability of the mesenchymal stem cells.…”

Section: Discussionmentioning

confidence: 99%

Exosomes Derived from microRNA-27a-3p Overexpressing Mesenchymal Stem Cells Inhibit the Progression of Liver Cancer through Suppression of Golgi Membrane Protein 1

Bongolo

Thokerunga

Yan³

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains a significant health burden to date. Its early diagnosis and treatment are complicated by the lack of early diagnosis markers and multidrug resistance. microRNA regulation of HCC oncogenes are among the new diagnostic and therapeutic strategies being explored, although the mode of delivery of a therapeutic dose of the miRNA remains a challenge. In this study, we explored the use of exosomes from umbilical mesenchymal stem cells transfected with miR-27a-3p to interact with the oncogene GOLM1 in HCC and inhibit HCC progression both in vitro and in vivo. We first determined and compared the expression levels of miR-27a-3p in blood, various cell lines and tissues of HCC and their corresponding normal controls. We then employed bioinformatics analysis to determine the gene target for miR-27a-3p in HCC and later transfected upregulated miR-27a-3p in mesenchymal stem cells, and treated HCC cells with exosomes extracted from the transfected stem cells. We then created mouse models of HCC using balbc/nude mice and equally treated them with exosomes from miR-27a-3p transfected stem cells. The results showed that miR-27a-3p is downregulated in blood, cell lines, and tissues of HCC patients compared to normal controls. Exosomes from the miR-27a-3p transfected mesenchymal stem cells prevented HCC cell proliferation, invasion, and metastasis both in vitro and in vivo. Upregulation of miR-27a-3p prevented HCC through interacting with and downregulating GOLM1 as its target oncogene. In conclusion, miR-27a-3p is a potential therapeutic target for HCC acting through GOLM1.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosomes Derived from microRNA-27a-3p Overexpressing Mesenchymal Stem Cells Inhibit the Progression of Liver Cancer through Suppression of Golgi Membrane Protein 1

Bongolo

Thokerunga

Yan³

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Currently, the therapeutic options for unresectable advanced liver cancer are not e cacious. Traditional non-surgical therapeutic methods, including chemotherapy and radiotherapy do not have satisfactory outcomes (18)(19)(20). New therapeutic options for liver cancer are constantly emerging, immunotherapy is among them (21).…”

Section: Discussionmentioning

confidence: 99%

CBX3 Is a Prognostic Biomarker That Is Correlated With Lymphocyte Infiltration in Hepatocellular Carcinoma

Zhang

Tao

Ding

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: CBX3 is a key gene that is involved in immune cell regulation, however, its prognostic values and its correlation with infiltrating lymphocytes in various cancers have not been clearly established. This study aims to investigate the role CBX3 in hepatocellular carcinoma (HCC).Methods: We first reviewed the expression of CBX3 in different cancers and adjacent tissues using oncomine database. Next, the authors focus on the expression of CBX3 in hepatocellular carcinoma. Therefore, the expression of CBX3 in hepatocellular carcinoma were analyzed through UALCAN online analysis website and the Human Protein Atlas (www.proteinatlas.org) website. In addition, we further found that CBX3 can be identified as an effective marker for the prognostic guidance of hepatocellular carcinoma according to the Kaplan-Meier plotter database and the Bioinformatics analysis online websites (www.aclbi.com). Next, we used the Bioinformatics analysis online websites to explore whether the expression level of CBX3 in liver cancer is related to the infiltration of certain immune cells. In addition, we also predicted the correlation between immune checkpoint and CBX3 in liver cancer.Results: The analysis results preliminarily show that CBX3 be expressed abnormally in many cancers, and CBX3 was significantly up-regulated in HCC. The high expression of CBX3 indicated survival outcomes and it showed a huge potential as a effective marker for the prognostic guidance of hepatocellular carcinoma. Furthermore, we found that CBX3 in liver cancer is related to the infiltration of certain immune cells, including CD4+ T cells, macrophages and B cells. In addition, the results showed HAVCR2 is most likely to become an effective immune checkpoint for HCC patients immunotherapy with high CBX3 expression.Conclusions: CBX3 is a potential diagnostic and prognostic marker in HCC and related to the infiltration of certain immune cells. It is expected to become a breakthrough point in immunotherapy in the future.

show abstract

“…In these studies, the potential of both the Amnio-M-derived cells and the AFCs to stimulate tissue repair was mediated by several paracrine mechanisms, such as the release of trophic factors [ 83 ], immunomodulation [ 84 , 85 ], and the establishment of a supportive environment for renewal [ 86 ]. Furthermore, both in vitro and in vivo studies showed that the derivatives and protein extracts of the AMSCs and hAECs display potent anti-tumor effects [ 87 – 89 ].…”

Section: Cellular Components Of the Amnio-mmentioning

confidence: 99%

Applications of the amniotic membrane in tissue engineering and regeneration: the hundred-year challenge

et al. 2022

Self Cite

View full text Add to dashboard Cite

The amniotic membrane (Amnio-M) has various applications in regenerative medicine. It acts as a highly biocompatible natural scaffold and as a source of several types of stem cells and potent growth factors. It also serves as an effective nano-reservoir for drug delivery, thanks to its high entrapment properties. Over the past century, the use of the Amnio-M in the clinic has evolved from a simple sheet for topical applications for skin and corneal repair into more advanced forms, such as micronized dehydrated membrane, amniotic cytokine extract, and solubilized powder injections to regenerate muscles, cartilage, and tendons. This review highlights the development of the Amnio-M over the years and the implication of new and emerging nanotechnology to support expanding its use for tissue engineering and clinical applications. Graphical Abstract

show abstract

Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives

Cited by 9 publications

References 193 publications

Exosomes Derived from microRNA-27a-3p Overexpressing Mesenchymal Stem Cells Inhibit the Progression of Liver Cancer through Suppression of Golgi Membrane Protein 1

Exosomes Derived from microRNA-27a-3p Overexpressing Mesenchymal Stem Cells Inhibit the Progression of Liver Cancer through Suppression of Golgi Membrane Protein 1

CBX3 Is a Prognostic Biomarker That Is Correlated With Lymphocyte Infiltration in Hepatocellular Carcinoma

Applications of the amniotic membrane in tissue engineering and regeneration: the hundred-year challenge

Contact Info

Product

Resources

About